TB-500
Case StudyCommunity knowledge about TB-500 captures what aggregated dosing diaries and self-reports reveal about real-world use. A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects. The patterns that emerge — dose ranges that produce response without diminishing returns, stack pairings that work and don't, sourcing tier that matches subjective response — are the practical wisdom not always captured in clinical literature.
Key Takeaways
Community lens: aggregated reports on TB-500 converge on incremental rather than dramatic effects over 4-8 weeks. Mechanism: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Reported non-response rate: 15-25% of users describe absent or partial response at 2-5 mg 1-2x weekly subq (loading phase); maintenance lower dosing. Community dose-range convergence: research-dose range produces modal response; substantial upward adjustment produces diminishing returns. Community-favoured stack partners: BPC-157, Ipamorelin, GHK-Cu.
Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. This influences cell migration during repair, angiogenesis, and stem-cell mobilisation. Acts systemically when injected anywhere, unlike many peptides whose effects are local. What the community actually reports about this mechanism in practice: incremental subjective effects over 4-8 weeks at the standard TB-500 dose, non-response rates of 15-25%, dosing-diary convergence on the research dose range, and stacking patterns that filter for well-tolerated combinations across many cycles.
Common dosing diary patterns
User dosing diaries converge on 2-5 mg as the standard, with experienced users sometimes adjusting upward by 25–50% and reporting diminishing returns thereafter. The diary patterns also show that subcutaneous administration is the dominant route, and that consistency matters more than absolute dose.
Stacking patterns and community wisdom
The most-reported TB-500 stack combinations rotate through Thymosin β4 fragment, Tβ4(17-23) and the canonical pairings appropriate to its mechanism. Community convergence on these patterns is one of the most useful signals for new users — not because the community is always right, but because the well-tolerated combinations have been filtered over many cycles.
What works and what doesn't
Honesty about non-response is one of the more useful contributions of community reporting. Roughly 15–25% of users report that TB-500 did not produce the expected effect for their specific use case. The most-cited reasons: dose timing relative to food, vendor quality issues, expectations calibrated to dramatic stories rather than the actual modest profile, and stacking complexity that masked the individual contribution.
Reconstitution Notes is one of the more-reported community use cases for TB-500. The aggregate experience pattern: most users report incremental benefit within 4–8 weeks, a minority report no response, and dramatic responses are rare. Setting expectations to the modal experience improves user satisfaction.
Community dosing diaries for TB-500 in first-person report converge on consistent dosing patterns. The shared wisdom is more useful than any individual report — not because the community is always right but because consistent patterns across many users filter idiosyncratic experiences.
For side effect reports, community first-cycle reports on TB-500 tend to undersell the response, while second-cycle reports tend to oversell. The honest middle is what experienced users describe — modest, consistent, and worth the protocol effort for users with baseline-appropriate indications.
Storage Tips is one of the more-reported community use cases for TB-500. The aggregate experience pattern: most users report incremental benefit within 4–8 weeks, a minority report no response, and dramatic responses are rare. Setting expectations to the modal experience improves user satisfaction.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 2-5 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 1-5 mg | 4–6 weeks initial cycle |
| Case Study focus | SubQ | 2-5 mg | 1-2x weekly SubQ (loading phase); maintenance lower |
| Maintenance phase | SubQ | 1-5 mg | Ongoing with periodic pauses |
Dose timing for TB-500 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
TB-500 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the experienced peptide community.
- TB-500 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with TB-500's mechanism in first-person / case studies protocols.
- TB-500 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with TB-500's mechanism in first-person / case studies protocols.
- TB-500 + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with TB-500's mechanism in first-person / case studies protocols.
- TB-500 + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with TB-500's mechanism in first-person / case studies protocols.
Generally well tolerated. Limited human safety data. Avoid in active cancer.
Lens-specific safety considerations for first-person / case studies use of TB-500: Generally well tolerated. Limited human safety data. Avoid in active cancer. Additional first-person / case studies monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | Case Study |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
Side effects users actually report?
Common mistakes new users make?
Is TB-500 a good first peptide?
How long until I notice effects?
What is the regulatory status of TB-500?
How does TB-500's half-life affect dosing?
Start a TB-500 Protocol
Alukard provides physician-supervised protocols with GMP-certified TB-500 and GMP-certified compounds dispensed with personalised dosing protocols.
Get ProtocolQuick Facts
- Molecular weight
- 888-1717 Da (depending on form)
- Sequence length
- 17 aa
- Half-life
- ~2-3 days
- WADA
- Banned (S0)
- FDA
- Unapproved
- Research
- Preclinical + veterinary clinical (equine)
Stack Partners
All first-person / case studies applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for TB-500 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your First-Person / Case Studies Protocol for TB-500
Alukard provides physician-supervised protocols with GMP-certified compounds dispensed with personalised dosing protocols.
HIPAA Compliant · GMP Certified · Physician Supervised